Doctors at the University of Chicago just got word that Tempus, a cancer fighting organization founded by Eric Lefkofsky, will provide advanced data testing to help treat breast cancer patients. In an announcement made on Thursday by Chicago-based Tempus, A partnership is in the works with the University of Chicago Medicine. The goal is to create treatment plans specific for each patient by providing molecular sequencing and analysis to the breast cancer specialists at the University of Chicago.
Tempus plans to analyze data from about 1,000 breast cancer patients in hopes to find patterns that will help doctors and researchers predict the treatment response of each patient. Over time, this will hopefully improve the outcome of treatment in patients by providing data that will help better fight cancer.With the current system, physicians are forced to make treatment decisions that aren’t backed by specific genetic information that could lead to better targeted treatment decisions for each patient. With Tempus, it helps doctors make personalized treatment decisions using machines that focus on genotypes.
The partnership with the University of Chicago is the latest of its kind. Tempus has ties with other universities as well including Northwestern University, Rush University, University of Pennsylvania, and the University of Michigan.Eric Lefkofsky is the co-founder and CEO of Tempus. Before starting the technology company in 2015, Lefkofsky co-founded Lightbank, a venture fund investing in the disruption of the technology industry. He is also the co-founder and Chairman of a global e-commerce marketplace, Groupon. He is co-founder of multiple other companies including Uptake Technologies, Mediaocean, Echo Global Logistics, InnerWorkings. Lefkofsky founded the private charitable foundation the Lefkofsky Family Foundation in 2006 with his wife Liz. The foundation has sparked initiatives in the community and has greatly impacted the quality and enhancement of comunities served.